一名接受6-氨基己酸治疗的前列腺癌患者出现肝坏死和心脏坏死。
Hepatic and cardiac necrosis in a patient with prostatic carcinoma given 6-aminocaproic acid.
作者信息
NOUR-ELDIN F, DRAISEY T F
出版信息
J Clin Pathol. 1963 Jan;16(1):61-4. doi: 10.1136/jcp.16.1.61.
Abstract
The pathological findings in a case of prostatic carcinoma with fibrinolysin, treated with epsilon-aminocaproic acid, included hepatic and cardiac necrosis. The possibility is discussed that the latter lesions may be a complication of epsilon-aminocaproic acid therapy or produced by the proteolytic action of the fibrinolysin.
摘要
一名接受ε-氨基己酸治疗的伴有纤维蛋白溶酶的前列腺癌患者的病理检查结果显示有肝坏死和心脏坏死。文中讨论了一种可能性，即后者这些病变可能是ε-氨基己酸治疗的并发症，或者是由纤维蛋白溶酶的蛋白水解作用所产生的。
相似文献
1
Hepatic and cardiac necrosis in a patient with prostatic carcinoma given 6-aminocaproic acid.
J Clin Pathol. 1963 Jan;16(1):61-4. doi: 10.1136/jcp.16.1.61.
2
[Research on the antifibrinolytic effect of 6-aminocaproic acid. III. Effect of 6-aminocaproic acid as an antidote to thrombolytic agents (plasmin, streptokinase)].
Gazz Int Med Chir. 1962 Nov 30;66:2444-50.
3
4
[Research on the antifibrinolytic action of 6-aminocaproic acid. I. Action in vitro of 6-aminocaproic acid].
Gazz Int Med Chir. 1962 Jul 31;66:1544-50.
5
[Hemostatic action of epsilon-aminocaproic acid. Experimental research].
Gazz Int Med Chir. 1963 Jan 15;67:61-70.
6
[Prevention and treatment by epsilon-aminocaproic acid of fibrinolytic syndromes in surgery].
Presse Med (1893). 1963 Apr 20;71:969-72.
7
Problems in hemostasis during openheart surgery. III. Epsilon amino caproic acid as an inhibitor of plasminogen activator activity.
Ann Surg. 1962 Feb;155(2):268-76. doi: 10.1097/00000658-196200000-00017.
8
[Acute fibrinolysis disclosing cancer of the prostate with bone metastases. Efficacy of epsilon-aminocaproic acid].
Bull Mem Soc Med Hop Paris. 1963;114:143-9.
9
[On the effect of 6-aminocaproic acid].
Wien Klin Wochenschr. 1962 Nov 9;74:771-4.
10
Epsilon-amino-caproic acid for hematuria in hemophilia.
J Lancet. 1962 Oct;82:421-4.
本文引用的文献
1
Factor 5 deficiency in hemorrhagic diathesis (parahemophilia).
J Am Med Assoc. 1952 Feb 9;148(6):462-3. doi: 10.1001/jama.1952.62930060003012b.
2
Activity of plasma labile factor in disease.
Lancet. 1951 Mar 17;1(6655):606-10. doi: 10.1016/s0140-6736(51)91115-4.
3
Formation of bradykinin in anaphylactic and peptone shock.
Am J Physiol. 1950 Nov;163(2):283-9. doi: 10.1152/ajplegacy.1950.163.2.283.
4
Clinical experiences with 6-aminocaproic acid (6-ACA) as an antifibrinolytic agent.
Acta Med Scand. 1961 Oct;170:487-509. doi: 10.1111/j.0954-6820.1961.tb00264.x.
5
Antifibrinolytic activity and metabolism of 6-aminocaproic acid in man.
Lancet. 1960 Jun 18;1(7138):1322-6. doi: 10.1016/s0140-6736(60)92305-9.
6
Fibrinolysis and fibrinolytic activity in man.
Physiol Rev. 1959 Apr;39(2):343-82. doi: 10.1152/physrev.1959.39.2.343.
7
The use of plasmin in the treatment of intravascular thromboses.
J Am Geriatr Soc. 1958 Feb;6(2):118-27. doi: 10.1111/j.1532-5415.1958.tb00694.x.
8
The biological significance of fibrinolysis.
Lancet. 1956 Sep 15;271(6942):565-8. doi: 10.1016/s0140-6736(56)92048-7.
Zotero 插件